ReviewCanadian journal of psychiatry. Revue canadienne de psychiatrie2017
Canadian Guidelines for the Pharmacological Treatment of Schizophrenia Spectrum and Other Psychotic Disorders in Children and Youth.
Review in Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 4 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- Clinical practice guidelines and quality standards for early intervention in psychosis: an AGREE II appraisal and systematic review of service components.Frontiers in psychiatry · 2026Pooled it
- Knowledge domain and trends in treatment-resistant schizophrenia (TRS) research based on CiteSpace bibliometrics analysis.Frontiers in pharmacology · 2024Pooled it
- A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia.CNS drugs · 2022Guideline
- Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis.European child & adolescent psychiatry · 2020Pooled it
- Efficacy and Safety of Blonanserin Oral Tablet in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study.Journal of child and adolescent psychopharmacology · 2022Trial
- Long-Term Safety and Efficacy of Blonanserin Oral Tablet in Adolescents with Schizophrenia: A 52-Week, Multicenter, Open-Label Extension Study.Journal of child and adolescent psychopharmacology · 2022Trial
- Supraventricular Tachycardia in an Adolescent with Acute Psychotic Disorder Treated with Olanzapine: A Rare Event Managed with Aripiprazole.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2026Article
- Antipsychotic treatment patterns and predictors of polypharmacy in psychotic disorders: 20-year real-world data from a tertiary center.Irish journal of medical science · 2026Article
- Lurasidone in Schizophrenia Management: A Comprehensive 12-Week Post-Marketing Surveillance Study in Chinese Patients.Neuropsychiatric disease and treatment · 2026Article
- Psychiatric Medications and QTc Prolongation in the Pediatric Population.Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent · 2025Article
- The treatment characteristics of oral antipsychotics in treatment of adolescents with schizophrenia in China.BMC psychiatry · 2025Article
- Safety and Tolerability of Brexpiprazole in Adolescents With Schizophrenia: A Long-Term, Open-Label Study.JAACAP open · 2025Article
- Clozapine, relapse, and adverse events: a 10-year electronic cohort study in Canada.The British journal of psychiatry : the journal of mental science · 2024Article
- Trends and off-label utilization of antipsychotics in children and adolescents from 2016 to 2021 in China: a real-world study.Child and adolescent psychiatry and mental health · 2024Article
- Training in Substance use Disorders, Part 1: Overview of Clinical Practice Recommendations.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2024Article
- Clozapine-induced myocarditis and subsequent rechallenge: a narrative literature review and case report.Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent · 2023Article
- Lost in Translation: Challenges in the Diagnosis and Treatment of Early-Onset Schizophrenia.Cureus · 2023Review
- Use of atypical antipsychotics in the treatment of schizophrenia in the Brazilian National Health System: a cohort study, 2008-2017.Epidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil · 2023Article
- Article
- Common practical questions - and answers - at the British Association for Psychopharmacology child and adolescent psychopharmacology course.Journal of psychopharmacology (Oxford, England) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveSchizophrenia spectrum and other psychotic disorders often have their onset in adolescence. The sequelae of these illnesses can negatively alter the trajectory of emotional, cognitive, and social development in children and youth if left untreated. Early and appropriate interventions can improve outcomes. This article aims to identify best practices in the pharmacotherapy management of children and youth with schizophrenia spectrum disorders.
methodsA systematic search was conducted for published guidelines for schizophrenia and schizophrenia spectrum disorders in children and youth (under age 18 years). Recommendations were drawn from the National Institute for Health and Care Excellence guidelines on psychosis and schizophrenia in children and youth (2013 and 2015 updates). Current guidelines were adopted using the ADAPTE process, which includes consensus ratings by a panel of experts.
resultsRecommendations identified covered a range of issues in the pharmacotherapy management of children and youth with schizophrenia spectrum disorders. Further work in this area is warranted as we continue to further understand their presentation in the developing brain.
conclusionsCanadian guidelines for the pharmacotherapy management of children and youth with schizophrenia spectrum disorders are essential to assist clinicians in treating this vulnerable population. Ongoing work in this area is recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.